Guggenheim Issues Pessimistic Forecast for Structure Therapeutics (NASDAQ:GPCR) Stock Price

Key Points

• Guggenheim has lowered its target price for Structure Therapeutics (NASDAQ:GPCR) from $92.00 to $90.00, maintaining a "buy" rating while indicating a potential upside of 454.12% from the last close.
• Structure Therapeutics' stock has seen a decline, trading down 0.4% to $16.24, with a twelve-month low of $13.22 and a high of $45.37.
• Despite the recent forecast adjustments, Structure Therapeutics maintains a consensus "buy" rating from analysts, reflecting continued bullish sentiment on its potential.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) had its target price decreased by equities research analysts at Guggenheim from $92.00 to $90.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's target price points to a potential upside of 454.12% from the stock's previous close.

A number of other research firms have also weighed in on GPCR. Citigroup assumed coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price on the stock. HC Wainwright dropped their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. JMP Securities reduced their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $77.86.

Structure Therapeutics Trading Down 0.4%

Structure Therapeutics stock traded down $0.07 during trading hours on Thursday, reaching $16.24. 935,191 shares of the stock were exchanged, compared to its average volume of 857,589. The stock has a 50 day moving average of $20.13 and a two-hundred day moving average of $22.05. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $45.37. The company has a market cap of $931.32 million, a P/E ratio of -18.59 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Deep Track Capital LP raised its position in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Vestal Point Capital LP grew its position in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after buying an additional 575,000 shares during the last quarter. Boxer Capital Management LLC bought a new position in shares of Structure Therapeutics during the fourth quarter valued at approximately $13,560,000. Pacific Heights Asset Management LLC purchased a new position in Structure Therapeutics during the 2nd quarter valued at $9,540,000. Finally, Marshall Wace LLP lifted its position in shares of Structure Therapeutics by 339.6% in the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock worth $15,817,000 after purchasing an additional 450,531 shares during the period. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.